ALLMedicine™ Prader-Willi Center
Research & Reviews 791 results
https://clinicaltrials.gov/ct2/show/NCT05322096
May 13th, 2022 - RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and being developed by Gedeon Richter Plc. for weight management. This will be the first Phase 2, proof-of-concept study using RGH-706 and is the third study ...
https://doi.org/10.2174/1871530322666220509225637
Endocrine, Metabolic & Immune Disorders Drug Targets; Sani E, Prato GD et. al.
May 12th, 2022 - Prader-Willi syndrome is the most frequent genetic cause of obesity and is often complicated by glucose metabolism alterations. Conventional therapies prescribed in type 2 diabetes frequently failed to achieve adequate glycemic control in patients...
https://doi.org/10.1002/ajmg.a.62770
American Journal of Medical Genetics. Part A; Nolan BJ, Proietto J et. al.
May 10th, 2022 - Hypogonadism is the most frequent hormonal deficiency in individuals with Prader-Willi syndrome (PWS). This often necessitates testosterone treatment, but limited data are available to guide testosterone treatment in adult men with PWS. We aimed t...
https://doi.org/10.1007/s12020-022-03064-1 10.1038/gim.2016.178 10.1111/j.1440-1754.2011.02225.x 10.1352/0895-8017(2006)111[193:Mips]2.0.Co;2 10.1111/j.1365-277X.2012.01275.x 10.1161/01.cir.0000437739.71477.ee 10.1111/cob.12135 10.2337/dc13-2575 10.1111/cen.14583 10.5694/mja13.00193 10.1186/s13023-020-01412-w 10.1111/cen.13933 10.1210/jc.2011-0038 10.1507/endocrj.ej12-0074 10.1111/j.1464-5491.2011.03280.x 10.6065/apem.2020.25.1.52 10.1016/j.diabres.2010.12.009 10.1002/pdi.1621 10.1111/ijpo.12131 10.1038/s41398-019-0597-0 10.1089/cap.2015.0240 10.1210/jc.2004-1651 10.1515/jpem.2010.140 10.1097/MPG.0b013e31805b82b5 10.1002/(sici)1096-8628(19971231)73:4<437::aid-ajmg12>3.0.co;2-s 10.3109/00048674.2011.580721 10.1016/s2213-8587(21)00002-4 10.1056/NEJMoa2032183
Endocrine Nolan BJ, Proietto J et. al.
May 8th, 2022 - Prader-Willi syndrome (PWS) is characterised by childhood-onset hyperphagia and obesity however limited data are available to guide treatment of obesity in this population. We aimed to evaluate the safety, tolerability, and efficacy of intensive m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077846
Orphanet Journal of Rare Diseases; Qian Y, Xia F et. al.
May 8th, 2022 - In recent years, more studies have observed that patients with Prader-Willi syndrome have lower insulin levels and lower insulin resistance than body mass index-matched controls, which may suggest protected glucose metabolism. The PubMed and Web o...
Guidelines 1 results
https://doi.org/10.1542/peds.2010-2820
Pediatrics McCandless SE,
Dec 29th, 2010 - This set of guidelines was designed to assist the pediatrician in caring for children with Prader-Willi syndrome diagnosed by clinical features and confirmed by molecular testing. Prader-Willi syndrome provides an excellent example of how early di...
Drugs 4 results see all →
Clinicaltrials.gov 37 results
https://clinicaltrials.gov/ct2/show/NCT05322096
May 13th, 2022 - RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and being developed by Gedeon Richter Plc. for weight management. This will be the first Phase 2, proof-of-concept study using RGH-706 and is the third study ...
https://clinicaltrials.gov/ct2/show/NCT05198362
Apr 11th, 2022 - For the double-blind portion of the study, dosing will be initiated in a subgroup of adults who are 18-65 years of age. Following independent Data Monitoring Board review of subgroup safety data, and review and confirmation to proceed by FDA, enro...
https://clinicaltrials.gov/ct2/show/NCT03848481
Dec 2nd, 2021 - This clinical research trial aims to study the efficacy and safety of cannabidivarin (CBDV), a naturally occurring homolog of the phytocannabinoid cannabidiol (CBD) in children and young adults with Prader-Willi Syndrome (PWS). CBDV has effects in...
https://clinicaltrials.gov/ct2/show/NCT03649477
Nov 17th, 2021 - This is a Phase 3 randomized, double-blind study with an 8-week, placebo-controlled period designed to test the effectiveness, safety, and tolerability of LV-101 in participants with PWS. Effectiveness will be measured using both caregiver-reporte...
https://clinicaltrials.gov/ct2/show/NCT05032326
Sep 28th, 2021 - This study is a prospective, multicentre, interventional cohort study in children with PWS over 4 years (no treatment administered). The duration of the preceding OTTB3 study is 26 weeks. An untreated cohort of children with PWS will be included a...
News 33 results
https://www.medpagetoday.com/psychiatry/generalpsychiatry/96750
Jan 19th, 2022 - While reporting bias persists, developers of new antidepressants have increasingly disclosed negative clinical trial outcomes. "Positive trials have always been reliably published, but negative trials, while common, have long been swept under the ...
https://www.medpagetoday.com/endocrinology/generalendocrinology/96457
Jan 2nd, 2022 - In the seemingly never-ending saga of metformin recalls, the FDA announced that Viona Pharmaceuticals voluntarily recalled 33 lots of metformin hydrochloride extended-release tablets 750 mg for NDMA impurity. Middle-age and older men with lower to...
https://www.medscape.com/viewarticle/963259
Nov 18th, 2021 - Signaling pathways in the cerebellum, rather than the hypothalamus, could provide a key for developing new therapies for the genetic disorder. What to know: Disordered signaling in the cerebellum may help explain the insatiable appetite experience...
https://www.medpagetoday.com/endocrinology/generalendocrinology/95477
Nov 5th, 2021 - An investigational carbetocin nasal spray for treating extreme hunger and other symptoms of Prader-Willi syndrome (PWS), a rare genetic disorder, received a near-unanimous thumbs-down from FDA advisors on Thursday. In a 12-1 vote, the agency's Psy...
https://www.medscape.com/viewarticle/962380
Nov 5th, 2021 - A US Food and Drug Administration (FDA) advisory panel has voted overwhelmingly against a new drug application (NDA) for intranasal carbetocin (Levo Therapeutics Inc.), intended to treat symptoms associated with Prader-Willi Syndrome (PWS). In a 1...
